American Journal of Infection Control

The current pandemic of coronavirus disease 2019 (COVID-19), has caused major strain on the U.S healthcare system, including home healthcare (HHC) agencies. HHC agencies faced numerous challenges during the early phase of the pandemic, including

Patients with end-stage renal disease (ESRD) and COVID-19 have increased risk of hospitalization and mortality (1, 2). Outpatient hemodialysis facilities are unique healthcare settings where patients receive therapy three times a week on shared

We read with great interest the recent manuscript by Hansen et al. describing the validation of an automated hand hygiene monitoring system (AHHMS).1 We agree with the authors’ statement that validation of system accuracy is critical to widespread

The authors would like to thank Moore et al. for their interest in our article. In their letter, they reference several interesting studies, but they do not meet all four methodological criteria suggested in our article. Importantly, the studies are

Initiatives to reduce rates of hospital-acquired infection (HAI) include care bundles focused on mitigating risk of ventilator-associated pneumonia (VAP) [1]. Ventilator-associated pneumonia is a preventable HAI estimated to affect 8-28% of intubated

Central line-associated bloodstream infections (CLABSI) occurring in intensive care units are associated with increased morbidity and mortality.1-3 These infections increase the length of hospital stay for an affected patient, as well as the cost of

Central line associated bloodstream infections (CLABSI) are preventable adverse events that result in significant harm including increased length of hospital stay, excess cost, and mortality; as such, CLABSI have become key quality indicators and

Urinary tract infections (UTIs) are common in both the inpatient and outpatient setting. The Centers for Disease Control and Prevention(CDC) reported in 2007 that UTI was the primary reason for 8.6 million ambulatory care visits, making them the most

By August 5, 2020, the United States approached 4.9 million confirmed cases of Coronavirus Disease 2019 (COVID-19) with more than 160,000 deaths.1 The pandemic created a significant disruption in the personal protective equipment (PPE) supply chain

Central venous catheters (CVCs) are widely used for the administration of chemotherapy to hematological and oncological patients. Central line-associated bloodstream infections (CLABSI) can be a serious cause of morbidity and mortality, with rates of